


Fig. 1

**Fig. 2**





Fig. 3

**Fig. 4**




Fig. 5




FIG. 6A





FIG. 6B





FIG. 6C


9/15

Control



(a)


CuCl<sub>2</sub>



(b)


FIG. 7A

**Asp-Cu-Asp (Æ-994)**



(c)


**Asp**



(d)


**FIG. 7B**

Thr-Cu-Thr



(e)


Thr



(f)


FIG. 7C

(Glu-Trp)<sub>2</sub>-Cu



(g)


Glu-Trp



(h)


FIG. 7D

His-Cu-His



(i)

His



(j)

FIG. 7E

**A: Effect on tumor volume**

**Saline-treated**



**Multiple Aa – Cu treated**



**B: Effect of vascularization (factor VIII immunochemistry)**

**Saline-treated**

**Multiple Amino-acid-Cu- treated**



**FIG. 8**




FIG. 9